ZGNX

MT1621

Thymidine Kinase 2 (TK2) Deficiency

Phase 2 (Open Label)

Exp Date

TBD

Amp Volatility Score

N/A

Catalyst Info & Data Links

Catalyst Events

  • TBA


Clinical Trial

  • NCT03845712: An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 (Continuation)


Time Line


Related Links


Prior Work



Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

ZGNX - Zogenix Provides Corpor...

Summary: FINTEPLA® (fenfluramine) oral solution launched in the U.S. in late July for Dravet syndrome with high enrollment of physicians and patients into the FINTEPLA Risk Evaluation and Mitigation S...

ZGNX - Positive CHMP Opinion f...

#ZGNX "announced that the Committee for Medicinal Products for Human Use (CHMP), a part of the European Medicines Agency (EMA), has adopted a positive opinion recommending the marketing authorization ...

ZGNX - Zogenix Announces Date ...

#ZGNX announced that it has changed the date of its previously announced earnings release and earnings call. The Company will now report its financial results for the three and nine months ended Septe...

ZGNX - Presents New Data for F...

Summary: Interim data from open-label extension trial showed substantial seizure reductions were maintained in patients treated with FINTEPLA® for up to two years Post-hoc analysis demonstrated NNTs (...

ZGNX - Zogenix to Release Thir...

#ZGNX "announced that it will report its financial results for the three and nine months ended September 30, 2020 and host a corporate update conference call and webcast after the market close on Tues...

ZGNX - Zogenix Announces Posi...

#ZGNX reported positive top-line results from its third Phase 3 study (Study 3) of FINTEPLA® (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome. The study corro...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon